Overview
Welcome to Immunicum's Investor Relations pages! Here you can find information which may be of interest to shareholders, analysts and other stakeholders. If you need more information or have any questions, please contact Erik Manting, CEO.
Phone: +46(0)8 732 8400
Email: ir@immunicum.com
CEO statement, August 26, 2021
“Immunicum has achieved steady momentum toward our clinical and corporate objectives in the first half of 2021. We will continue our path to address difficult-to-treat established tumors and tumor recurrence, which we believe represent the biggest challenges for today’s cancer therapy. Immunicum’s novel therapeutic approaches are based on intratumoral immune priming and relapse vaccination, with products showing promising efficacy in solid and blood-borne tumors, combined with an excellent safety profile. We have a rich, advanced clinical pipeline, strong in-house research and process development capabilities and leading science in allogeneic dendritic cell biology, with multiple ongoing clinical studies and upcoming clinical milestones to support a competitive clinical development strategy. During the last six months, Immunicum has moved closer to the realization of becoming a fully integrated biopharmaceutical company.”– Erik Manting, CEO
Investor Downloads
